Gonorrhea: New challenges

Clinics in Dermatology

Volumn 32, Issue 2, 2014, Pages 275-281

  Skerlev, Mihael ^a   Čulav Košćak, Ivana ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b General Hospital Ivo Pedi i   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RESISTANCE, BACTERIAL; GONORRHEA; HUMANS; INCIDENCE; NEISSERIA GONORRHOEAE;

EID: 84894079674     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.08.010     Document Type: Note

References (74)

1. Ison C.A. Biology of Neisseria gonorrheae ant the Clinical Picture of Infection. Sexually Transmitted Infections and Sexually Transmitted Diseases 2011, 77-90. Springer-Verlag, Berlin. G. Gross, S.K. Tyring (Eds.).
2. Criss A.K., Seifert H.S. A bacterial siren song: Intimate interactions between neutrophils and pathogenic Neisseria. Nat Rev Microbiol 2012, 10:178-190.
3. Urban C.F., Lourido S., Zychlinsky A. How do microbes evade neutrophil killing?. Cell Microbiol 2006, 8:1687-1696.
4. Jarvis G.A., Vedros N.A. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun 1987, 55:174-180.
5. Jack D.L., Dodds A.W., Anwar N., et al. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol 1998, 160:1346-1353.
6. Kahler C.M., Martin L.E., Shih G.C., Rahman M.M., Carlson R.W., Stephens D.S. The (alpha2)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun 1998, 66:5939-5947.
7. Review Virji M. Pathogenic neisseriae: Surface modulation, pathogenesis and infection control. Nat Rev Microbiol 2009, 7:274-286.
8. Söderholm N., Vielfort K., Hultenby K., Aro H. Pathogenic Neisseria hitchhike on the uropod of human neutrophils. PLoS One 2011, 6:e24353.
9. Boulton I.C., Gray-Owen S.D. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 2002, 3:229-236.
10. Pantelic M., Kim Y.J., Bolland S., Chen I., Shively J., Chen T. Neisseria gonorrhoeae kills carcinoembryonic antigen-related cellular adhesion molecule 1 (CD66a)-expressing human B cells and inhibits antibody production. Infect Immun 2005, 73:4171-4179.
11. Zen K., Parkos C.A. Review. Leukocyte-epithelial interactions. Curr Opin Cell Biol 2003, 15:557-564.
12. Wiesner P.J., Thompson S.E. Review. Gonococcal diseases. Dis Mon 1980, 26:1-44.
13. European Centre for Disease Prevention and Control (ECDC) Sexually transmitted infections in Europe 1990-2010 2012, ECDC, Stockholm, Accessed April 3, 2013. http://www.ecdc.europa.eu/en/publications/Publications/201206-Sexually-Transmitted-Infections-Europe-2010.pdf.
14. Health Protection Agency (HPA) Sexually transmitted infections in men who have sex with men in the UK: 2011 report 2011, HPA, London, Accessed April 3, 2013. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317131685989.
15. Health Protection Agency (HPA) New data show sexually transmitted infection diagnoses on the rise in England 2012, [Press release], HPA, London, Accessed April 3, 2013. http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1317134411572.
16. Savage E.J., Marsh K., Duffell S., Ison C.A., Zaman A., Hughes G. Rapid increase in gonorrhoea and syphilis diagnoses in England in 2011. Euro Surveill 2012, 17:1-4. Accessed April 3, 2013. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20224.
17. Trienekens S.C., Koedijk F.D., van den Broek I.V., et al. Sexually transmitted infections, including HIV, in the Netherlands in 2011 [RIVM report no. 201051001/2012] 2012, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, Accessed April 3, 2013. http://www.rivm.nl/dsresource?objectid=rivmp:181418&type=org&disposition=inline.
18. Velicko I., Arneborn M., Blaxhult A. Syphilis epidemiology in Sweden: Re-emergence since 2000 primarily due to spread among men who have sex with men. Euro Surveill 2008, 13:1-5. Accessed April 3, 2013. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19063.
19. Velicko I., Unemo M. Increase in reported gonorrhoea cases in Sweden, 2001-2008. Euro Surveill 2009, 14. Accessed April 3, 2013. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19315.
20. Van de Laar M., Spiteri G. Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe. Euro Surveill 2012, 17:1-3. Accessed April 3, 2013. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20225.
21. Health Protection Agency (HPA) Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales (GRASP) report of 2010 data. Health Protection Report 2011, 5. Accessed April 3, 2013. http://www.hpa.org.uk/hpr/archives/2011/hpr3711.pdf.
22. European Centre for Disease Prevention, Control (ECDC) Gonococcal antimicrobial susceptibility surveillance in Europe - 2010 2012, ECDC, Stockholm, Accessed April 3, 2013. http://ecdc.europa.eu/en/publications/Publications/1206-Gonococcal-AMR.pdf.
23. Centers for Disease Control and Prevention (CDC). Gonococcal infections. Accessed April 3, 2013. http://www.cdc.gov/std/treatment/2010/gonococcal-infections.htm.
24. Centers for Disease Control and Prevention (CDC). 2010 sexually transmitted diseases surveillance: Gonorrhea. Accessed April 3, 2013. http://www.cdc.gov/std/stats10/gonorrhea.htm.
25. Kerle K.K., Mascola J.R., Miller T.A. Disseminated gonococcal infection. Am Fam Physician 1992, 45:209-214.
26. Little J.W. Gonorrhea: Update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101:137-143.
27. National Institute of Allergy and Infectious Diseases. Gonorrhea. Accessed April 3, 2013. http://www.niaid.nih.gov/topics/gonorrhea/Pages/default.aspx.
28. Mulye T.P., Park M.J., Nelson C.D., Adams S.H., Irwin C.E., Brindis C.D. Trends in adolescent and young adult health in the United States. J Adolesc Health 2009, 45:8-24.
29. Centers for Disease Control and Prevention. 2009 Sexually transmitted diseases surveillance: Gonorrhea. Accessed April 3, 2013. http://www.cdc.gov/STD/stats09/gonorrhea.htm.
30. AVERT.org. STD statistics worldwide. Accessed April 3, 2013. http://www.avert.org/stdstatisticsworldwide.htm.
31. World Health Organization. Emergence of multi-drug resistantNeisseria gonorrhoeae: Threat of global rise in untreatable sexuallytransmitted infections. Accessed April 3, 2013. http://whqlibdoc.who.int/hq/2011/WHO_RHR_11.14_eng.pdf.
32. World Health Organization. Initiative for vaccine research (IVR). Accessed April 3, 2013. http://www.who.int/vaccine_research/diseases/soa_std/en/index2.html.
33. Goodyear-Smith F. What is the evidence for non-sexual transmission of gonorrhoea in children after the neonatal period? A systematic review. J Forensic Leg Med 2007, 14:489-502.
34. Martin I.M., Foreman E., Hall V., Nesbitt A., Forster G., Ison C.A. Non-cultural detection and molecular genotyping of Neisseria gonorrhoeae from a piece of clothing. J Med Microbiol 2007, 56:487-490.
35. Da Ros C.T., Schmitt Cda S. Global epidemiology of sexually transmitted diseases. Asian J Androl 2008, 10:110-114.
36. Ison C., Martin D. Gonorrhea. Atlas of sexually transmitted diseases and AIDS 2003, 109-125. Mosby, Edinburgh. S.A. Morse, R.C. Ballard, K.K. Holmes, A.A. Moreland (Eds.).
37. Cook R.L., Hutchison S.L., Ostergaard L., et al. Systematic review: Noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005, 142:914-925.
38. Whiley D.M., Garland S.M., Harnett G., et al. Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae. Sex Health 2008, 5:17-23.
39. Moran J.S. Treating uncomplicated Neisseria gonorrhoeae infections: Is the anatomic site of infection important?. Sex Transm Dis 1995, 22:39-47.
40. Manavi K., Young H., McMillan A. The outcome of oropharyngeal gonorrhoea treatment with different regimens. Int J STD AIDS 2005, 16:68-70.
41. Unemo M., Nicholas R.A. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012, 7:1401-1422.
42. Barry P.M., Klausner J.D. The use of cephalosporins for gonorrhea: The impending problem of resistance. Expert Opin Pharmacother 2009, 10:555-577.
43. Tapsall J., Whiley D., Sloots T. Applications of molecular testing in clinical laboratories for the diagnosis and control of gonorrhea. Future Microbiol 2006, 1:317-324.
44. Hall C., McElroy M., Samuel M., et al. Single-dose, oral cefpodoxime proxetil is effective for treatment of uncomplicated urogenital and rectal gonorrhea 2007.
45. Bignell C., Fitzgerald M. Guideline Development Group. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011, 22:541-547.
46. Lewis D.A. The gonococcus fights back: Is this time a knock out?. Sex Transm Infect 2010, 86:415-421.
47. Unemo M., Shafer W.M. Antibiotic resistance in Neisseria gonorrhoeae: Origin, evolution, and lessons learned for the future. Ann NY Acad Sci 2011, 1230:E19-E28.
48. Handsfield H.H., McCormack W.M., Hook E.W., et al. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med 1991, 325:1337-1341.
49. Palmer H.M., Young H., Winter A., Dave J. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Antimicrob Chemother 2008, 62:490-494.
50. Workowski K.A., Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59(RR-12):1-110.
51. Centers for Disease Control and Prevention (CDC) Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012, 61:590-594.
52. Tapsall J.W., Ndowa F., Lewis D.A., Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009, 7:821-834.
53. Chisholm S.A., Dave J., Ison C.A. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 2010, 54:3812-3816.
54. Starnino S., Stefanelli P. Neisseria gonorrhoeae Italian Study Group I. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J Antimicrob Chemother 2009, 63:1200-1204.
55. Galarza P.G., Abad R., Canigia L.F., et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2010, 54:1652-1653.
56. Katz A.R., Komeya A.Y., Soge O.O., et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: Case report of the first isolate identified in the United States. Clin Infect Dis 2012, 54:841-843.
57. Ndowa F., Lusti-Narasimhan M., Unemo M. The serious threat of multidrug-resistant and untreatable gonorrhoea: The pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect 2012, 88:317-318.
58. World Health Organization, Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Accessed October 6, 2012. http://www.who.int/reproductivehealth/publications/rtis/9789241503501.
59. Hobbs M.M., Sparling P.F., Cohen M.S., Shafer W.M., Deal C.D., Jerse A.E. Experimental gonococcal infection in male volunteers: Cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC. Front Microbiol 2011, 2:123.
60. Guiliani M.M., Adu-Bobie J., Comanducci M., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103:10834-10839.
61. Zhu W., Chen C.J., Thomas C.E., Anderson J.E., Jerse A.E., Sparling P.F. Vaccines for gonorrhea: Can we rise to the challenge. Front Microbiol 2011, 2:124.
62. Hadad R., Jacobsson S., Pizza M., et al. Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae. APMIS 2012, 120:750-760.
63. Borges O., Lebre F., Bento D., Borchard G., Junginger H.E. Mucosal vaccines: Recent progress in understanding the natural barriers. Pharm Res 2010, 27:211-223.
64. Newman L.M., Moran J.S., Workowski K.A. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007, 44(Suppl 3):S84-S101.
65. Stoltey J.E., Barry P.M. The use of cephalosporins for gonorrhea: An update on the rising problem of resistance. Expert Opin Pharmacother 2012, 13:1411-1420.
66. Furuya R., Onoye Y., Kanayama A., et al. Antimicrobial resistance in clinical isolates of Neisseria subflava from the oral cavities of a Japanese population. J Infect Chemother 2007, 13:302-304.
67. Saika T., Nishiyama T., Kanayama A., et al. Comparison of Neisseria gonorrhoeae isolates from the genital tract and pharynx of two gonorrhea patients. J Infect Chemother 2001, 7:175-179.
68. Tanaka M., Nakayama H., Huruya K., et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Int J Antimicrob Agents 2006, 27:20-26.
69. Ohnishi M., Saika T., Hoshina S., et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Japan Emerg Infect Dis 2010, 17:148-149.
70. Golparian D., Fernandes P., Ohnishi M., Jensen J.S., Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains including those with various high-level antimicrobial resistance - potential treatment option for gonorrhea?. Antimicrob Agents Chemother 2012, 56:2739-2742.
71. Roblin P.M., Kohlhoff S.A., Parker C., Hammerschlag M.R. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother 2010, 54:1358-1359.
72. Waites K.B., Crabb D.M., Duffy L.B. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 2009, 53:2139-2141.
73. Unemo M., Golparian D., Limnios A., et al. In vitro activity of ertapenem vs. ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants - ertapenem for treatment of gonorrhea?. Antimicrob Agents Chemother 2012, 56:3603-3609.
74. Hook E.W., Shafer W., Deal C., Kirkcady R.D. Iskander. CDC grand rounds: The growing threat of mulridrug-resistant gonorrhea. MMWR Morb Mortal Wkly Rep 2013, 62:103-106.